EV-Based Liquid Biopsy Market to Grow at 9.58% CAGR through 2029
An increase in
funding from government and private institutions to eradicate cancer is expected
to drive the Global EV-Based Liquid Biopsy Market growth in the forecast
period, 2025-2029.
According to
TechSci Research report, “EV-Based Liquid Biopsy Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”,
the Global EV-Based Liquid Biopsy Market stood at USD 89.10 Million in
2023 and is anticipated to project steady growth in the forecast period with a
CAGR of 9.58% through
2029. The global EV-Based Liquid Biopsy market is expected to grow in the next
few years due to several factors that shape its growth and trajectory. The
urgent need for improved cancer diagnostics and treatment monitoring, and the
advancements in technology and data analysis have significantly enhanced the
sensitivity and specificity of EV-based liquid biopsy tests that drives the
demand for EV-based liquid biopsy.
The growing
investment and research in the field of oncology and liquid biopsy technology
are also major drivers for the EV based liquid biopsy market. Pharmaceutical
companies, diagnostic laboratories, and biotechnology firms are actively
investing in the development of EV-based liquid biopsy products, leading to a
competitive market landscape, and driving innovation in the field. This leads
to a surge in the EV Based liquid biopsy market in the coming years.
Also, the rise
in cancer incidence worldwide has created a substantial market opportunity for
EV-based liquid biopsy. As cancer cases continue to rise, there is an
increasing need for precise, non-invasive diagnostics such as liquid biopsy to
help with early detection, patient follow-up, and disease management.
Many countries
have launched national cancer research programs and funding initiatives to
support research in oncology, which includes exploring novel diagnostic methods
like liquid biopsies. These programs aim to promote the development of
innovative technologies that can aid in early cancer detection, monitoring, and
personalized treatment strategies. As liquid biopsy technologies, including
EV-based approaches, gain traction in the scientific community, they could
potentially receive support through these existing cancer research initiatives.
Also, regulatory agencies in different countries play a vital role in shaping the
environment for medical technologies, including liquid biopsy tests. They work
to ensure the safety, efficacy, and quality of medical devices and diagnostics,
which includes liquid biopsy assays. By providing clear guidelines and pathways
for regulatory approval, governments can facilitate the adoption and
commercialization of advanced liquid biopsy technologies, including those based
on EVs. This results in boosting the EV-Based Liquid Biopsy market in the
coming years.
However, there
are several challenges faced by the EV-Based Liquid Biopsy market. One of the
primary challenges is the technical complexities associated with isolating and
characterizing EVs from biofluids. The process can be labor-intensive, prone to
variability, and requires standardization to ensure consistent and reliable
results. Another key challenge is the identification of specific and reliable
biomarkers within EVs that can accurately indicate different cancer types and
stages. The heterogeneity of EVs and the dynamic nature of cancer present
complexities in pinpointing consistent and universally applicable biomarkers.
Extensive research and validation efforts are needed to discover and validate
reliable EV-based biomarkers that can be used effectively for cancer diagnosis
and monitoring. Also, Proper sample handling and storage are critical
challenges as well. EVs are sensitive to degradation and can be affected by
improper collection, handling, and storage, leading to compromised data quality
and inaccurate results. Maintaining standardized procedures for sample handling
is essential to maintain the integrity of EVs and their cargo. Lastly,
cost-effectiveness is a significant challenge for the widespread adoption of
EV-based liquid biopsy. The development, validation, and commercialization of
these tests can be expensive, and efforts to optimize production processes and
reduce costs are needed to make the technology more accessible to a broader
population. These challenges lead to a decline in the EV Based liquid biopsy
market in the coming years.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global EV-Based Liquid Biopsy Market”
The Global EV-Based
Liquid Biopsy Market is segmented into offering, workflow, technology, sample
type, end user, regional distribution, and company
Based on the sample
type, global EV-Based Liquid Biopsy market is segmented into blood, urine,
saliva, and others. The dominant sample type for EV-Based Liquid Biopsy is Blood.
Blood is likely to be the dominant sample type in the EV-based liquid biopsy
market. Blood offers a rich source of circulating EVs, and its ease of
collection makes it a preferred choice for non-invasive cancer detection and
monitoring, driving its dominance in the market. The blood-based liquid
biopsies provide a holistic view of systemic health, allowing for the detection
of cancer and other diseases at early stages, when treatment options are most
effective. Additionally, blood samples are relatively stable and amenable to
processing and storage, enabling convenient transportation and analysis in
centralized laboratories.
Based on region,
while other regions such as Europe and Asia Pacific are also witnessing rapid
growth in the adoption of EV-based liquid biopsy technologies, North America
remains at the forefront due to its robust research infrastructure, strong
regulatory environment, and high demand for advanced diagnostic solutions.
North America's large patient population, coupled with high healthcare
expenditure, drives significant demand for advanced diagnostic technologies for
cancer and other diseases. Liquid biopsy assays, including those based on
extracellular vesicles (EVs), offer non-invasive and sensitive tools for early
cancer detection, treatment monitoring, and personalized medicine, thereby
gaining traction among healthcare providers and patients alike. Strategic
collaborations between academia, industry, and government agencies facilitate
the translation of research findings into clinically actionable liquid biopsy
assays. These collaborations foster innovation, drive market growth, and contribute
to North America's leadership position in the Global EV-Based Liquid Biopsy
Market.
Major companies
operating in Global EV-Based Liquid Biopsy Market are:
- Horiba Ltd.
- Thermo Fisher
Scientific, Inc.
- Lonza Group AG
- Takara Bio Inc.
- Abcam plc
- Qiagen N.V.
- Malvern
Panalytical Ltd.
- Revvity, Inc.
(PerkinElmer, Inc)
- Norgen Biotek
Corp.
- Bio-Techne
Corporation
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“North America
was likely the dominant region for the EV-based liquid biopsy market. The
region's dominance can be attributed to several factors, including a robust
healthcare infrastructure, high investments in cancer research and precision
medicine, and a strong presence of key players in the biotechnology and
diagnostics industries. Additionally, North America has a large pool of
patients and healthcare providers eager to adopt innovative diagnostic
technologies, leading to early adoption and commercialization of EV-based
liquid biopsy products. This results in boosting the EV-based liquid biopsy
market in the coming years”, said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“EV-Based Liquid Biopsy Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering (Kits &
Assays, Services, Instruments), By Workflow (Sample Preparation, Sequencing,
Data Analysis), By Technology (Isolation Technologies, Analysis Technologies),
By Sample Type (Blood, Urine, Saliva, and Others), By End user (Academic and
Research Institutes, Pharmaceutical and Biotechnology Companies, Clinical
Laboratories), By Region and Competition, 2019-2029F”,
has evaluated the future growth potential of Global EV-Based Liquid Biopsy
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global EV-Based Liquid
Biopsy Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com